EUVIMEDEUVIMED entdecken
Crossref

Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy

Jie Ma, Tao Chen, Jianning Zhang, Weidong Cao, Gan Gao, Xinguang Yu, Hongwei Wang

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03435-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Jie Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: PLA Medical School, Beijing, 100853, People's Republic of China. Hauptthemen laut MEDLINE: Craniopharyngioma, Brachytherapy, Pituitary Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Managing residual and recurrent craniopharyngioma effectively is crucial for improving patient outcomes. This study evaluates the combined use of gamma knife and phosphorus-32 brachytherapy, offering insights into alternative, less invasive treatment strategies. METHODS: We conducted a retrospective analysis of 97 patients treated from 2010 to 2016 for residual and recurrent craniopharyngioma using gamma knife and phosphorus-32 brachytherapy. We classified these patients into three groups: superficial solid (Group A), simple cystic (Group B), and mixed cystic-solid (Group C). We assessed the treatment's effectiveness by the tumor control rates and evaluated safety by monitoring vision, endocrine function improvements, and complication rates. RESULTS: The treatment achieved complete and adequate control rates of 49.5% and 87.6%, respectively. We observed improvements in vision or visual fields in 55.1% of the patients. The morbidity rate was 15.5%. The study found no significant differences in tumor control rates among the various lesion types. CONCLUSION: The combination of gamma knife and phosphorus-32 brachytherapy presents a viable, minimally invasive alternative for treating residual and recurrent craniopharyngioma. It offers high tumor control and functional improvement rates, suggesting its potential as a preferred strategy in some instances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CraniopharyngiomaBrachytherapyPituitary NeoplasmsNeoplasm Recurrence, LocalRadiosurgeryNeoplasm, ResidualHumansRetrospective StudiesFemaleMaleAdultMiddle AgedAdolescentChildYoung AdultPhosphorus RadioisotopesChild, PreschoolAgedCombined Modality TherapyTreatment Outcome

Stichwörter der Autor:innen

BrachytherapyCraniopharyngiomaPhosphorus-32RecurrentResidual

Substanzen

Phosphorus Radioisotopes

Autor:innen und Institutionen

  • PLA Medical School, Beijing, 100853, People's Republic of China.
  • Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China.
  • State Key Laboratory of Industrial Control Technology, Zhejiang University, Hangzhou, 310027, People's Republic of China.
  • Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China. yuxinguang_301@163.com.
  • Department of Neurosurgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China. wanghongweidoc@sina.com.

Zitieren

APA

Ma, J., Chen, T., Zhang, J., Cao, W., Gao, G., Yu, X., & Wang, H. (2024). Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03435-2

Vancouver

Ma J, Chen T, Zhang J, Cao W, Gao G, Yu X, et al. Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03435-2

BibTeX
@article{Ma2024,
  author = {Ma, Jie and Chen, Tao and Zhang, Jianning and Cao, Weidong and Gao, Gan and Yu, Xinguang and Wang, Hongwei},
  title = {Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03435-2}
}
Kostenlos starten →